Decentralized and incentivized healthcare Revolutionary AI & a sophisticated dual blockchain model

A fully operational medical ecosystem
A cutting-edge social medical network
Videochat, medical records, trackers, appointments, prescriptions
eLearning, scientific research & professional medical IT

Join us fighting cancer and get paid for living a healthier life!
Aimedis is already revolutionizing healthcare and is live in hospitals across Europe and Asia

Official presale live -
get your 19% bonus now!

5 ETH minimum contribution, 25% extra bonus if you HODL 12 months!

ICO bench
Aimedis ICO rating

Subscribe, and don't miss on Token Sale Announcements

Token presale has started

Token for Sale

300,000,000 AIM

Total Amount

600,000,000 AIM

Price / Token

0,12 USD

Airdrop program is finished


big pharma companies

> 20



Hospital chains



Token Summary


Use of Revenue

57% Development
16% Operations
13% Marketing
8% Reserves
6% Legal


AIM Token Allocations

50% ICO crowd sale
20% Community initiatives, marketing & legal
20% Team, supporters & advisory board
5% Legal reserve
5% Reserve

Welcome to Aimedis

Aimedis is an AI backed, blockchain and smart contract supported medical ecosystem, that changes the way patients, doctors, and hospitals communicate, connect and handle information.

Using the Aimedis platform, users can store, secure and share their medical information only with the people they want to share it with by using the Aimedis right management system.

Beside the records, AImedis offers videochat and communication with other patients and doctors, online prescriptions, online appointments, learning content, the inclusion of fitness trackers and devices like ECG or bloodpressure monitors into the system, while all transactions inside the system are backed by our porprietary AIMChain blockchain.

Aimedis is running in hospitals across Europe and Asia and is supporting scientific research to save lives

The token

The AIM token is used in several ways.

First, AIM holders will participate in the Aimedis health ecosystem and will be able to benefit from its applications and functionalities.

Second the pharmaceutical industry and scientific research facilities can pay patients a fee for participating in trials by granting access to dedicated areas of their medical records, which is 100% voluntary.

In the next step Aimedis will release AIMSocial, the platform that incentivises patients for helping and engaging with other patients.

Fair and incentivised support by patients for patients - worldwide.

Aimedis Roadmap

2012 - 2015 TheHealthNet/IhrArzt24 research project with over 10.000 patients

AIMEDIS - the team

From and with doctors for patients, resident colleagues and hospitals
Dr. Michael J. Kaldasch
CEO, MD & founder
Dr. Ben El Idrissi
COO, MD & founder
Sankar Ghanesh
Dr. Lazaros Fountoukidis
Roxana Nasoi, M.Sc
Dr. Stefan F. Krieg
Physicist - HPC, deep learning & AI
Lin Wan, M.Sc.
Head of IT & development
Amer Mufti
Head of Silicon Valley office - lead blockchain development
Sebastian Wehkamp, M.A.
CDO & creative director
Benjamin Bergmann
Sopia Singdee
BD Asia
Catherine Angcaya, M.A.,LL.C
Daria Borisenko, B.A.
BD Russia, Belarus & Ukraine
BingFeng Liu, B.Sc.
Full stack developer
ZiLong Sun, B.Sc.
Full stack mobile developer
Markus Moench, M.Sc, B.Sc.
Full stack developer
Gang Zhu, B.Sc.
Full stack developer
Dr. Yang Chul Boering
Project leader hospitals & MD
Yohei Negi

AIMEDIS - the board

Meet our board
Prof. Dr. Volker Hömberg
Neurologist, president WFNR
Prof. Dr. Maximilian Mehdorn
Prof. Dr. Hartmut Gülker
Prof. Dr. Thomas Druyen
Director of the Institute for Future Psychology and Future Management
Prof. Dr. Michael Philippi
Former CEO Sana Kliniken AG
Prof. Dr. Georg Sabin
Prof. Dr. Hubertus Heuer
Prof. Dr. Berhard Breil
Health IT scientist
Prof. Simon Choi, LLB, LLM, CPEC
Top global ICO lawyer
Prof. Dr. Timo Schinkoethe
Biologist & Computer scientist, founder of Cankado
Rui Dong
Key advisor at the Blockchain Association of Canada
Miguel Sanchez de Pedro
Banking expert
Rizmy Shariff
Investment & ICO specialist
Stefan Bergstroem
ICO advisor
Danny Christ
ICO advisor
Hilary Egwuagu
ICO advisor

Aimedis - ICO Documents

White Paper
EN    CN    KN    JP    RU    VN

One Pager



Token Purchase Agreement

Frequently Asked Questions

If you don't find answers to your questions here, please write us at [email protected]
Aimedis is based in the Netherlands and Switzerland to meet the highest regulatory standards and security for both users and investors.
Storing medical data in highly encrypted and secured databases grants an added level of security, transparency and efficiency of transfer. The core principles the blockchain is built on are well suited for the transfer of health data as they achieve a multi-purpose environment, which existing solutions cannot guarantee. Our proprietary AIMChain is a testament to this. Every single operation, every single access to patients’ data, every change can be tracked and is 100% traceable for patient and medical professionals – inside the platform – patients can see in a diagram when, where and why a doctor or a hospital has accessed their data and what changes have been made. That is the AIMChain!
In contrast to a lot of competitors in general and especially in the medical field we offer a fully working platform and not just an idea. Based on our 2012 developed Platform TheHealthNet/IhrArzt24 (rolled out in Germany and German speaking countries) which worked as our experimental platform for 3 years we gathered information and experience working with institutions and patients. In addition we rely on our well-developed network of connections in Europe emphasizing that the Aimedis founder worked in Germany and France for years which are the biggest health care markets in Europe. Since last year we are focusing on Asia and concentrating in building a powerful network which will help us grow in Asian countries.
Aimedis operates its business in the Netherlands, Switzerland, Germany and Thailand but will expand to more countries in the next 2 years. We are already operating a development office in Mountain View, Silicon Valley to be close its unique entrepreneurial and development spirit.
Artificial intelligence (AI) will, and already is, revolutionizing the way we live, work and succeed. Medicine is one of the major use cases for AI where it will improve diagnoses, therapies and research at a level, no human being can reach. Even today AI can diagnose CT and MRI images much better than the best medical professionals. In future, AI will be a major part of the way our medical ecosystem will enhance patients’ and doctors’ lives. Initially AI will support doctors when it comes to enhancing medication, recognizing possible drug interactions and optimizing dosage regarding sex, age, weight, diagnoses (e.g. kidney failure) and in a later stage pharmacogenetic predispositions (e.g. slow vs. rapid metabolizers). AIMedibots will continually crawl the anonymous parts of our secured databases to gather new insights, for e.g. on unknown possible drug interactions or side effects regarding certain diagnoses and conditions. The larger our database the more significance the gathered information will have. As we start our cooperation with several hospital chains in a short time, we will grow our database quickly and AI will have quite some work to do. In a later stage, Aimedis V3.0 project Excalibur, Aimedis will introduce AI supported diagnoses and therapies in cooperation with university hospitals.
AIM token sale details
There will be 600.000.000 AIM token in total, from which 300.000.000 will be distributed in the AIM token sale. Exceeding the target will be returned to the participating ETH wallet after the tokensale process has ended.
The value of the AIM token after the ICO can’t be predicted now and will be determined by the market evaluation which is the case in most ICOs in the cryptomarket.
If the full 300.000.000 tokens are not sold during the ICO, only the sold amount of AIM token will be issued and the remaining ones will be burned so the total amount of existing tokens depends on the results of the ICO.
Anyone can participate in AIM’s tokensale. Before taking part please make sure you are eligible to participate in the Aimedis tokensale depending on your jurisdiction. In general, residents of the United States and Singapore can’t participate in tokensales. Even if you are not a resident of United States and Singapore, please be sure to check if there are any regulatory restrictions in your country or state.
The AIM token sale process
To participate in the AIM token sale, please sign up to our newsletter and our social media channels to be updated on a regular base and whitelist to qualify for the presale and the ICO. When the presale has started you will be able to log into your account you created during the whitelisting. After login you will be instructed how to contribute.
Ethereum and Bitcoin can be purchased on a lot of cryptocurrency exchanges. Please visit coinmarketcap.com for more information.
The minimum amount to contribute during the presale equals to 5 ETH or 0.5 BTC. If you send less than 5 ETH or 0.5 BTC in the presale you will be moved to the ICO participant list.
The minimum amount to contribute during the main ICO equals to 0.1 ETH or 0.01 BTC. If you send less than 0.1 ETH or 0.01 BTC the amount will be refunded to the original ETH address in full.
AIM tokens will be distributed and allocated in the order of the transactions received from the specified address. The tokens are distributed to ERC20.
This will depend on the actual value of ETH and BTC, 1 AIM = 0,12 USD
Unfortunately it is not possible to return ETH / BTC once it’s send to a specific address so you have to make sure you check the correct ETH / BTC address before you send it. You can ONLY contribute via our website. No other website or channel will show any contribution address so any address outside our personal login area is NOT ours. Aimedis is NOT responsible for lost ETH / BTC and will not refund them.
There is no separate refund process except in the case where the fundraised amount exceeds the maximum amount.
The AIM token
Aimedis plans to list the AIM token in several exchanges, so please stay tuned for more information coming up after the ICO.
The AIM token wallet will be available soon after the ICO. We will also announce it on our social media channel.

AIMEDIS B.V. - Contact us

Sint Michaëlstraat 4, 5935 BL Steyl, Netherlands

You subscribed successfully.